New studies confirm the lower levels of vitamin D are associated with a higher risk of developing diabetes and diabetic retinopathy.
New studies confirm that lower levels of vitamin D are associated with a higher risk of developing diabetes and diabetic retinopathy. But the mechanisms by which vitamin D may affect progression, beta cell function, dysglycemia, and retinopathy are not clear. Researchers say prospective vitamin D supplementation trials are the next step, not ad hoc treatment with vitamin D.
"We see an inverse association with serum vitamin D levels and diabetic retinopathy in children with type 1 diabetes," said Maria Craig, PhD, School of Women's and Children's Health, University of New South Wales, Sydney, Australia. "But it is unclear why and our results do not suggest wholesale vitamin D supplementation for anyone, child or adult, with diabetes."
Dr Craig presented 1 of 3 studies linking lower serum levels of vitamin D with increased risk for diabetes or diabetes complications at the American Diabetes Association's 71st Scientific Sessions in San Diego. Her group found that children with type 1 diabetes who were deficient in vitamin D at double the risk for retinopathy compared to similar children with normal serum levels of vitamin D. Vitamin D deficiency was not associated with abnormal peripheral nerve function or elevated albumin excretion rate/albumin-to-creatinine ratio. Her results echo earlier findings in adults with type 2 diabetes. Biologic models suggest that increased levels of vitamin D inhibit neovascularization and angiogenesis, which protects the retina, but there are no clinical data.
Canadian researchers found an association between higher levels of vitamin D and improved beta-cell function and lower glucose levels after 3 years of follow up. Higher baseline vitamin D significantly reduced the odds ratio for progression to type 2 diabetes even after adjustment for baseline body mass index (BMI) and changes to BMI over the 3-year follow-up period.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More